75847-73-3 (依那普利,Enalapril)

依那普利;苯酯丙脯酸;(S)-1-(N-(1-(乙氧羰基)-3-苯丙基)-L-丙氨酰基)-L-脯氨酸;

Enalapril;Amprace;Renitec;Vaseretic;Vasotec;Enalapril Maleate;(R)-3-((1-methylpyrrolidin-2-yl)methyl)-5-(2-(phenylsulfonyl)ethyl)-1H-indole;(R)-5-(2-phenylsulphonylethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole;[3H]-Eletriptan;3-(N-methyl-2(R)-pyrrolidinylmethyl)-5-(2-phenylsulphonylethyl)-1H-indole;Eletriptan;Eletriptan (INN);Eletriptan [INN:BAN];eletriptanum;N-[(S)-1-(ethoxycarbonyl)-3-phenylpropyl]-L-alanyl-L-proline;N-[1-(S)-(ethoxycarbonyl)-3-phenylpropyl]alanylproline;Relpax;(S)-(−)-1-[N-(1-Ethoxycarbonyl-3-phenylpropyl)-L-alanyl]-Lproline;(S)-1-(N-(1-(Ethoxycarbonyl)-3-phenylpropyl)-L-alanyl)-L-proline;1-(N-((S)-1-Carboxy-3-phenylpropyl)-L-alanyl)-L-proline 1'-ethyl ester;MK-421;D07892;NS00008385;Spectrum2_001455;SPBio_001349;Nalpha -[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl-L-proline;Spectrum3_001478;KBio2_001787;NINDS_000408;BRD-K57545991-050-23-1;N-((1S)-1-(ethoxycarbonyl)-3-phenylpropyl)-L-alanyl-;1-[2-(1-Ethoxycarbonyl-3-phenyl-propylamino)-propionyl]-pyrrolidine-2-carboxylic acid(enalapril);BPBio1_000340;ENALAPRIL (MART.);CAS-75847-73-3;2-[2-(1-Carboxy-3-phenyl-propylamino)-propionyl]-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid(enalapril);H10947;N-[(2S)-1-Ethoxy-1-oxo-4-phenyl-2-butanyl]-L-alanyl-L-proline;BRD-K57545991-050-24-9;N-(1(S)-Ethoxycarbonyl-3-phenylpropyl)-L-alanyl-L-proline;Enalaprila;KBio3_002535;Enalaprilum;(2S)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]pyrrolidine-2-carboxylic acid;GTPL6322;NCGC00021569-06;UNII-69PN84IO1A;DB00584;NCGC00021569-05;(S)-1-[N-[1-(ethoxycarbonyl)-3- phenylpropyl]-L-alanyl]-L-proline;(S)-1-((S)-2-(((S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl)amino)propanoyl)pyrrolidine-2-carboxylicacid;CHEBI:4784;C06977;DTXSID5022982;AB00053615-18;KBio2_004355;Bonuten;((S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)-L-alanyl-L-proline;SBI-0051691.P002;Gadopril;ENALAPRIL [INN];L-Proline, N-((1S)-1-(ethoxycarbonyl)-3-phenylpropyl)-L-alanyl-;(S,S,S)-1-[2-(1-Ethoxycarbonyl-3-phenyl-propylamino)-propionyl]-pyrrolidine-2-carboxylic acid;EN300-7481394;BIDD:GT0751;N-{(1S)-1-[(ethyloxy)carbonyl]-3-phenylpropyl}-L-alanyl-L-proline;Enalapril (TN);BRD-K57545991-050-16-5;Enalaprila (INN-Spanish);ENALAPRIL [WHO-DD];(S)-1-((S)-2-(1-((S)-Ethoxycarbonyl)-3-phenyl-propylamino)-propionyl)-pyrrolidine-2-carboxylic acid;(2S)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]pyrrolidine-2-carboxylic acid;AB00053615-17;IDI1_000408;1-[2-(1-Ethoxycarbonyl-3-phenyl-propylamino)-propionyl]-pyrrolidine-2-carboxylic acid;HSDB 6529;Spectrum_001307;HMS2090E08;KBioGR_000355;(S)-1-{(S)-2-[1-((S)-Ethoxycarbonyl)-3-phenyl-propylamino]-propionyl}-pyrrolidine-2-carboxylic acid;Enalaprilum (Latin);Enalaprila [INN-Spanish];DivK1c_000408;NCGC00021569-04;L-Proline, 1-(N-(1-(ethoxycarbonyl)-3-phenylpropyl)-L-alanyl)-, (S)-;Enaladex;Prestwick3_000314;CAS-76095-16-4;Spectrum5_001107;ENALAPRIL [VANDF];Q422185;Enalapril Richet;(S)-1-((S)-2-(((S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl)amino)propanoyl)pyrrolidine-2-carboxylic acid;Enalapril [INN:BAN];Enalapril (INN);Enalapril, AldrichCPR;AB00053615_19;69PN84IO1A;Tox21_110872_1;1-[2-(1-Ethoxycarbonyl-3-phenyl-propylamino)-propionyl]-pyrrolidine-2-carboxylic acid (Enalapril);(SSS)1-[2-(1-Ethoxycarbonyl-3-phenyl-propylamino)-propionyl]-pyrrolidine-2-carboxylic acid;SCHEMBL18;NCGC00016932-01;(S)-1-[(R)-2-((R)-1-Ethoxycarbonyl-3-phenyl-propylamino)-propionyl]-pyrrolidine-2-carboxylic acid;KBioSS_001787;AKOS025310615;75847-73-3;Epaned;C09AA02;Enalaprilum (INN-Latin);L-Proline, N-[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]-L-alanyl-;KBio1_000408;AB00053615_20;CHEMBL578;ENALAPRIL [MI];BSPBio_000308;BDBM50017129;Olinapril;ENALAPRIL [MART.];Spectrum4_000008;BSPBio_003035;Enalaprilum [INN-Latin];analapril;DTXCID202982;Tox21_110872;N-[1-(S)-ethoxycarbonyl-3-phenylpropyl]-L-alanyl-L-proline;KBio2_006923;NCGC00021569-09;N-[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]-L-alanyl-L-proline;N-((2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)-L-alanyl-L-proline;HY-B0331;(S)-1-((S)-2-((R)-1-ethoxy-1-oxo-4-phenylbutan-2-ylamino)propanoyl)pyrrolidine-2-carboxylic acid;

MFCD00865774

GBXSMTUPTTWBMN-XIRDDKMYSA-N

InChI=1S/**********/c1-3-27-20(26)16(12-11-15-8-5-4-6-9-15)21-14(2)18(23)22-13-7-10-17(22)19(24)25/h4-6,8-9,14,16-17,21H,3,7,10-13H2,1-2H3,(H,24,25)/t14-,16-,17-/m0/s1

O=C(O)[C@H]1N(C([C@H](C)N[C@H](C(OCC)=O)CCC2=CC=CC=C2)=O)CCC1

方法1:α-氧代苯丁酸乙酯和L-丙氨酰-L-脯氨酸二肽在4A分子筛作用下缩合,生成Schiff’s碱,再用氰硼氢化钠还原即得依那普利,如进一步和马来酸成盐可得马来酸依那普利。 方法2:也可用α-溴代苯丁酸乙酯和L-丙氨酰-L-脯氨酸二肽在二甲基甲酰胺溶液中,三乙胺作用下缩合,一步即可得到依那普利。 方法3:上述方法均需苯丁酸的衍生物,在原料受限制时可采用下面的方法。 用丁烯二酸酐对苯进行酰化,生成伊苯甲酰丙烯酸,收率90.1%。 β-苯甲酰丙烯酸、无水乙醇、苯和浓硫酸,回流分水。****溶液中和,饱和氯化钠和水洗,干燥,过滤。滤液减压浓缩,蒸馏收集148～150℃/133Pa的馏分,得β-苯甲酰丙烯酸乙酯,收率97.3%。 β-苯甲酰丙烯酸乙酯、丙氨酸苄酯对甲苯磺酸盐、无水乙醇和三乙胺混合,在室温下搅拌。过滤出固体,烘干得化合物(I),收率75%。 化合物(I)、硫酸、冰乙酸和10%钯-炭催化剂,通氢。过滤,滤液减压浓缩至干,碱处理后洗涤。用乙酸乙酯重结晶,得化合物(Ⅱ),收率52.6%。 化合物(Ⅱ)和N-羟基琥珀酰亚胺溶于二甲基甲酰胺,冰浴冷却下分批加入二环己基碳化二亚胺(DCC),在室温下搅拌。冰浴冷却下加入L-脯氨酸四甲基铵盐的二甲基甲酰胺溶液,反应。滤去固体,用酸碱处理后,用乙酸乙酯提取。提取液干燥,减压浓缩。残液溶于乙腈,加入马来酸的乙腈溶液,充分搅拌后放置过夜。滤得固体,用乙腈重结晶,得白色针状结晶的马来酸依那普利,收率46.7%。 上面的化合物...